ロード中...
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797–9. ©2018 AACR....
保存先:
| 出版年: | Cancer Discov |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6345252/ https://ncbi.nlm.nih.gov/pubmed/29967074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0489 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|